Lupin Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/hu5qedfmw4jrrvneopv2wk3h.pdf

Key Takeaways


U.S. Business: The Tolvaptan Reset & What Comes Next

Vinita Gupta: "Revenue should remain at a billion dollars plus, which is a bar that we want to be able to maintain."

Apixaban Oral Suspension: The Next Big Bet


India Formulations: Chronic Share Ambition Keeps Rising

Nilesh Gupta: "I would love to prove you wrong. Our plans add up to around 70%, but that does not mean we stop there. We are a chronic story and that is where growth will come from."

Margins: Holding the Line Today, Investing for Tomorrow

Ramesh Swaminathan: "It is clearly because of that in the Americas, but there is a mix change in other parts. Moreover, there have been tailwinds in terms of forex associated with the impact on gross margins..."

Pipeline & Portfolio Evolution: Building Durability

Vinita Gupta: "Investments in areas like specialty, particularly in Europe, as well as biosimilars and 505(b)(2)s, give us confidence that we should be able to evolve our developed markets business toward a more durable and sustainable portfolio, as opposed to one-off exclusives."

Regional & Other Performance

RegionTrendCommentary
Other Developed Markets▲ Strong46% YoY growth led by strong sales in Australia, Canada, and Europe; Europe delivered double-digit growth even without VISUfarma contribution.
Emerging Markets▼ Declined4% YoY de-growth with lower sales in Brazil, where Dapagliflozin faced additional competition after two years of strong upsides, offsetting double-digit growth in South Africa, Philippines, and Mexico.
VISUfarma acquisition▲ ClosedContributing to Europe performance; the acquisition was a key driver of the net cash reduction from ₹4,636 crores to ₹3,349 crores, along with dividend payouts.
Gross margin tailwinds▲ ForexQ2 benefited from forex tailwinds because forwards taken in Q1 at ~89–90 had depressed Q1 realizations; the unwind provided a sequential lift.
Other Operating Income▼ LowerDeclined ~81% YoY primarily due to lower export benefits from PLI schemes.

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 U.S. revenueUSD 1.1 bn to USD 1.2 bnFY27
FY27 EBITDA marginAround 24–25%FY27
H2 organic growth ex-U.S.Around 20%H2 FY27
U.S. pipeline filingsMore than 15 productsFY27
U.S. launchesMore than 60 products, including ~25 injectable/respiratory, 5 biosimilars, 2–3 505(b)(2)sNext 3 years
Apixaban Oral Suspension launchQ1 FY28FY28
FY28 U.S. revenue floorAt least USD 1 bn plusFY28
FY29 U.S. revenueMaintain USD 1 bn run rateFY29
India chronic share~70%Next 5 years
India novel products shareOne-third of India revenuesNext 10 years
India growth vs. IPM1.2x to 1.3x IPM growth rateOngoing
Full-year R&D spendAround 8% of salesFY27
Full-year ETRAround 27–28%FY27
Long-term EBITDA margin29–30%FY29–30 timeframe
Spiriva Respimat® filingThis fiscal yearFY27
Breo Ellipta filingLater this fiscal year, possibly Q1 FY28FY27 / early FY28
Etanercept U.S. filingLater this fiscal yearFY27
Biosimilar U.S. filings4–5 productsNext few years

Key Metrics

MetricQ2 FY27
Revenue from operations₹7,827 cr, +11% YoY
U.S. sales$317 million, -13.4% QoQ constant currency; +9.3% YoY
India formulations growth14.7% YoY; core prescription business +13.8% YoY
Other Developed Markets revenue₹1,182 cr, +46% YoY; 15% of total revenue
Emerging Markets growth-4% YoY
API growth~20% YoY
Gross margin74.2%, vs 73.3% in Q2FY26 and 74.6% in Q1FY27
EBITDA margin25.1%, vs 31.3% in Q2FY26; FY27 guidance of 24–25%
R&D spend7.9% of sales (₹618 cr); FY27 guidance ~8%
Employee benefit expenses18.3% of sales (₹1,424 cr), vs 16.2% in Q2FY26
Manufacturing and other expenses31.3% of sales (₹2,438 cr), vs 29.0% in Q2FY26
India chronic share~66% of portfolio in H1FY27, up from ~65% in FY26
India chronic growth19.5% in H1FY27 vs IPM growth of 17.2%
India volume growth6.1% in H1FY27
Net cash₹3,349 cr as of Sep 30, vs ₹4,636 cr on Mar 31, 2026
Operating working capital87 days, vs 90 days in Q1FY27
Effective tax rate28.5% in H1FY27; FY27 guidance 27–28%
U.S. FY27 revenue guidance$1.1 bn – $1.2 bn; Q1 and Q2 above plan
U.S. FY28 revenue expectationAt least $1 bn
Tolvaptan market share~50% in recent months as sole generic
India prescription sales force~11,400 people
India H1FY27 outperformance vs IPM~1.16x (14.4% vs 14.3% IPM growth)
Diabetes segment growth25%+ YoY in Q2; third consecutive quarter of 20%+ growth
Anti-Diabetes segment outperformance1.5x category growth in H1FY27
Cardiac segment outperformance1.1x category growth in H1FY27
Dermatology segment outperformance1.5x category growth in H1FY27
European business growth45% YoY
Other Operating Income₹42 cr, -81% YoY from ₹216 cr in Q2FY26
H1FY27 U.S. revenue$683 mn (per an analyst's math)
Implied H2FY27 U.S. quarterly run rate~$230 mn to hit guidance midpoint (per an analyst's math)
Apixaban brand market size$10 bn+
Capital deployment capacityUp to ~₹20,000 cr (2x EBITDA debt threshold plus balance sheet cash)
India products launched in H1FY2712; plan ~20 for full year FY27